Asciminib – Uses, Dosage, Side Effects, Interaction

Last updated: February 8, 2026Reviewed date: February 8, 2026Reading time: 43 min read
Patient Tools

Read, save, and share this guide

Use these quick tools to make this medical article easier to read, print, save, or share with a family member.

Asciminib - Uses, Dosage, Side Effects, Interaction
Patient Mode

Understand this article easily

Switch between simple English and easy Bangla patient notes. This is for education and does not replace a doctor consultation.

Asciminib is an orally bioavailable, allosteric Bcr-Abl1 tyrosine kinase inhibitor, with antineoplastic activity. Upon administration, asciminib targets and binds to the myristoyl pocket of the Bcr-Abl1 fusion protein at a location that is distinct from the ATP-binding domain, thereby inhibiting the activity of both wild-type Bcr-Abl and certain...

For severe symptoms, danger signs, pregnancy, child illness, or sudden worsening, seek urgent medical care.

বাংলা রোগী নোট এখনো যোগ করা হয়নি। পোস্ট এডিটরে “RX Bangla Patient Mode” বক্স থেকে সহজ বাংলা সারাংশ যোগ করুন।

এই তথ্য শিক্ষা ও সচেতনতার জন্য। এটি ডাক্তারি পরীক্ষা, রোগ নির্ণয় বা প্রেসক্রিপশনের বিকল্প নয়।

Article Summary

Asciminib is an orally bioavailable, allosteric Bcr-Abl1 tyrosine kinase inhibitor, with antineoplastic activity. Upon administration, asciminib targets and binds to the myristoyl pocket of the Bcr-Abl1 fusion protein at a location that is distinct from the ATP-binding domain, thereby inhibiting the activity of both wild-type Bcr-Abl and certain mutation forms, including the T315I mutation. This binding results in the inhibition of Bcr-Abl1-mediated proliferation and enhanced apoptosis of Philadelphia...

Key Takeaways

  • This article explains Mechanism of Action in simple medical language.
  • This article explains Indications in simple medical language.
  • This article explains Contraindications in simple medical language.
  • This article explains Dosage in simple medical language.
Educational health guideWritten for patient understanding and clinical awareness.
Reviewed content workflowUse writer and reviewer profiles for stronger trust.
Emergency safety firstUrgent warning signs are highlighted below.
Choose your reading view

Patient View highlights a simple learning journey. Clinical View reveals structure, evidence, and editorial completeness.

Seek urgent medical care if you notice

These warning signs are general safety guidance. Local emergency numbers and clinical judgment should always come first.

  • Severe symptoms, breathing difficulty, fainting, confusion, or rapidly worsening illness.
  • New weakness, severe pain, high fever, or symptoms after a serious injury.
  • Any symptom that feels urgent, unusual, or unsafe for the patient.
1

Emergency now

Use emergency care for severe, sudden, rapidly worsening, or life-threatening symptoms.

2

See a doctor

Book a professional medical evaluation if symptoms persist, worsen, recur often, affect daily activities, or occur in a high-risk patient.

3

Learn safely

Use this article to understand possible causes, tests, treatment options, prevention, and questions to ask your clinician.

Before reading

RX Patient Tools

Use these quick guides before reading the article, or return to them when you need help preparing questions for a doctor.

Start here Choose the right pathway for symptoms, reports, medicines, or urgent warning signs. Disease article roadmap Read this topic step by step: meaning, symptoms, warning signs, diagnosis, treatment, prevention, and follow-up. Treatment planner Prepare questions about treatment choices, benefits, risks, side effects, and follow-up. Family & caregiver guide Organize symptoms, reports, medicines, questions, and follow-up safely. Nutrition & diet guide Prepare food, hydration, supplement, and medicine-timing questions safely. Prevention guide Organize risk factors, protective habits, screening, and warning signs. Recovery guide Prepare a safe plan for activity, rehabilitation, warning signs, and follow-up.
Definition

Asciminib is an orally bioavailable, allosteric Bcr-Abl1 tyrosine kinase inhibitor, with antineoplastic activity. Upon administration, asciminib targets and binds to the myristoyl pocket of the Bcr-Abl1 fusion protein at a location that is distinct from the ATP-binding domain, thereby inhibiting the activity of both wild-type Bcr-Abl and certain mutation forms, including the T315I mutation. This binding results in the inhibition of Bcr-Abl1-mediated proliferation and enhanced apoptosis of Philadelphia chromosome-positive (Ph+) hematological malignancies. The Bcr-Abl1 fusion protein tyrosine kinase is an abnormal enzyme produced by leukemia cells that contain the Philadelphia chromosome.

Asciminib is a tyrosine kinase inhibitor (TKI) used in the treatment of chronic-phase Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML). More specifically, it is an inhibitor of the ABL1 kinase activity of the BCR-ABL1 fusion protein which serves as a driver of CML proliferation in most patients with the disease. It has also shown benefit in Ph+ CML with the T315I mutation, which produces a mutant BCR-ABL1 which is typically treatment-resistant as compared to wild-type BCR-ABL1. Existing inhibitors of ABL compete at the ATP binding sites of these proteins and can be classified into those that target the active conformation of the kinase domain ([dasatinib], [bosutinib]) and those that target the inactive kinase domain ([imatinib], [nilotinib], [ponatinib]). Asciminib is unique in that it acts as an allosteric inhibitor, binding at the myristoyl pocket of the BCR-ABL1 protein and locking it into an inactive conformation. Asciminib received FDA approval on October 29, 2021 (Scemblix, Novartis AG).

Asciminib Hydrochloride is the hydrochloride salt form of asciminib, an orally bioavailable, allosteric Bcr-Abl1 tyrosine kinase inhibitor, with antineoplastic activity. Upon administration, asciminib targets and binds to the myristoyl pocket of the Bcr-Abl1 fusion protein at a location that is distinct from the ATP-binding domain, thereby inhibiting the activity of both wild-type Bcr-Abl and certain mutation forms, including the T315I mutation. This binding results in the inhibition of Bcr-Abl1-mediated proliferation and enhanced apoptosis of Philadelphia chromosome-positive (Ph+) hematological malignancies. The Bcr-Abl1 fusion protein tyrosine kinase is an abnormal enzyme produced by leukemia cells that contain the Philadelphia chromosome.

Mechanism of Action

In most patients with chronic myeloid leukemia (CML), progression of the disease is driven primarily by a translocation of the Philadelphia chromosome that creates an oncogenic fusion gene, _BCR-ABL1_, between the _BCR_ and _ABL1_ genes. This fusion gene produces a resultant fusion protein, BCR-ABL1, which exhibits elevated tyrosine kinase and transforming activities that contribute to CML proliferation. Asciminib is an allosteric inhibitor of the BCR-ABL1 tyrosine kinase. It binds to the myristoyl pocket of the ABL1 portion of the fusion protein and locks it into an inactive conformation, preventing its oncogenic activity.

Indications

  • Asciminib is indicated for the treatment of adult patients with Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) in the chronic phase who have been previously treated with ≥2 tyrosine kinase inhibitors. It is also indicated in the treatment of Ph+ CML in adult patients with the T315I mutation.
  • Scemblix is indicated for the treatment of adult patients with Philadelphia chromosome-positive chronic myeloid leukemia in the chronic phase (Ph+ CML CP) previously treated with two or more tyrosine kinase inhibitors
  • Myeloid Leukemia, Chronic, Chronic Phase

Use in Cancer

Asciminib hydrochloride is approved to treat adults with:

  • Chronic myelogenous leukemia (CML) is in chronic phase and is Philadelphia chromosome positive. It is used:
    • In patients who have received at least two tyrosine kinase inhibitors.¹
    • In patients whose CML has the T315I mutation.

This use is approved under FDA’s Accelerated Approval Program. As a condition of approval, confirmatory trial(s) must show that asciminib hydrochloride provides a clinical benefit in these patients.

Asciminib hydrochloride is also being studied in the treatment of other types of cancer.

Contraindications

The following conditions are contraindicated with this drug. Check with your physician if you have any of the following:

  • anemia
  • decreased blood platelets
  • low levels of a type of white blood cell called neutrophils
  • high blood pressure
  • pregnancy
  • a patient who is producing milk and breastfeeding
  • pancreatitis
  • high blood levels of the lipase enzyme
  • high blood levels of the amylase enzyme

Dosage

Strengths: 20 mg; 40 mg

Chronic Myelogenous Leukemia

Philadelphia chromosome-positive chronic myeloid leukemia I chronic phase (Ph+ CML-CP):

  • Ph+ CML-CP Previously Treated with 2 or More TKIs (tyrosine kinase inhibitors): 80 mg orally once a day OR 40 mg orally every 12 hours
  • Duration of therapy: Continue as long as clinical benefit is observed or until unacceptable toxicity occurs
  • Ph+ CML-CP with the T315I Mutation: 200 mg orally every 12 hours
  • Mild to severe renal impairment (eGFR 15 to 89 mL/min/1.73 m2): No adjustment recommended
  • ESRD (eGFR less than 15 mL/min/1.73 m2) Data not available

Dose Adjustments

Dose Reductions for Adverse Reactions:

Ph+ CML-CP Previously treated with 2 or more TKIs:

  • FIRST REDUCTION: 40 mg once a day OR 20 mg twice a day
  • SUBSEQUENT REDUCTION: Permanently discontinue in patients unable to tolerate a reduced dose

Ph+ CML-CP with T315I Mutation:

  • FIRST REDUCTION: 160 mg twice a day
  • SUBSEQUENT REDUCTION: Permanently discontinue in patients unable to tolerate a reduced dose

platelet count, which can increase bleeding risk. সহজ বাংলা: প্লাটিলেট কম।" data-rx-term="thrombocytopenia" data-rx-definition="Thrombocytopenia means low platelet count, which can increase bleeding risk. সহজ বাংলা: প্লাটিলেট কম।">THROMBOCYTOPENIA and/or bacterial infection. সহজ বাংলা: ব্যাকটেরিয়ার বিরুদ্ধে লড়াই করা শ্বেত রক্তকণিকা।" data-rx-term="neutrophil" data-rx-definition="Neutrophil is a white blood cell important for fighting bacterial infection. সহজ বাংলা: ব্যাকটেরিয়ার বিরুদ্ধে লড়াই করা শ্বেত রক্তকণিকা।">neutrophil count, which may increase infection risk. সহজ বাংলা: নিউট্রোফিল কম থাকা, সংক্রমণের ঝুঁকি বাড়তে পারে।" data-rx-term="neutropenia" data-rx-definition="Neutropenia means low neutrophil count, which may increase infection risk. সহজ বাংলা: নিউট্রোফিল কম থাকা, সংক্রমণের ঝুঁকি বাড়তে পারে।">NEUTROPENIA: Absolute Neutrophil Count (ANC) less than 1 x 10(9)/L and or Platelets (PLT) less than 50 x 10(9)/L:

  • HOLD therapy until resolved to ANC of 1 x 10(9)/L or greater and/or PLT of 50 x 10(9)/L or greater
  • If resolved within 2 weeks: Resume at the starting dose
  • If resolved after more than 2 weeks: Resume at a reduced dose

For recurrent severe platelet count, which can increase bleeding risk. সহজ বাংলা: প্লাটিলেট কম।" data-rx-term="thrombocytopenia" data-rx-definition="Thrombocytopenia means low platelet count, which can increase bleeding risk. সহজ বাংলা: প্লাটিলেট কম।">thrombocytopenia and/or bacterial infection. সহজ বাংলা: ব্যাকটেরিয়ার বিরুদ্ধে লড়াই করা শ্বেত রক্তকণিকা।" data-rx-term="neutrophil" data-rx-definition="Neutrophil is a white blood cell important for fighting bacterial infection. সহজ বাংলা: ব্যাকটেরিয়ার বিরুদ্ধে লড়াই করা শ্বেত রক্তকণিকা।">neutrophil count, which may increase infection risk. সহজ বাংলা: নিউট্রোফিল কম থাকা, সংক্রমণের ঝুঁকি বাড়তে পারে।" data-rx-term="neutropenia" data-rx-definition="Neutropenia means low neutrophil count, which may increase infection risk. সহজ বাংলা: নিউট্রোফিল কম থাকা, সংক্রমণের ঝুঁকি বাড়তে পারে।">neutropenia, hold until resolved ANC is 1 x 10(9)/L or greater and PLT is 50 x 10(9)/L or greater, then resume at a reduced dose
ASYMPTOMATIC AMYLASE and/or LIPASE ELEVATION: Elevation greater than 2 x ULN:

  • HOLD until resolved to less than 1.5 x ULN
  • If resolved, restart at a reduced dose; if the event recurs at a reduced dose, permanently discontinue
  • If not resolved, permanently discontinue; perform diagnostic tests to exclude pancreatitis

NON-HEMATOLOGIC ADVERSE REACTIONS: Grade 3 or higher:

  • HOLD until recovery to Grade 1 or less
  • If resolved, resume at a reduced dose
  • If not resolved, permanently discontinue

Side Effects

The Most Common

  • muscle, bone or joint pain
  • tiredness
  • nausea
  • diarrhea
  • unexpected bleeding or easy bruising, blood in urine or stools
  • fever or signs of an infection
  • sudden stomach pain or discomfort, nausea or vomiting
  • confusion, headaches, dizziness, chest pain, or shortness of breath
  • rash, difficulty breathing or swallowing, swelling of face, lips or tongue, rash or skin flushing, dizziness or feeling faint, fever, fast heartbeat
  • shortness of breath, chest pain or pressure, feeling of rapid or irregular heart beat, ankle or feet swelling, weight gain, numbness or weakness on one side of the body, decreased vision or loss of vision, trouble talking, pain in arms, legs, back, neck or jaw

More Common

  • heart problems–pain in your arms, legs, back, neck or jaw, numbness or weakness on one side of your body, problems with speech or vision, dizziness, headache, swelling in your ankles or feet, chest pain, irregular heartbeat, rapid weight gain, feeling short of breath, severe stomach pain;
  • high blood pressure–severe headache, blurred vision, pounding in your neck or ears;
  • low blood cell counts–fever, chills, tiredness, flu-like symptoms, mouth sores, skin sores, easy bruising, unusual bleeding, pale skin, cold hands and feet; or
  • pancreas problems–sudden stomach pain or discomfort, nausea, or vomiting.
  • cold symptoms such as stuffy nose, sneezing, sore throat;
  • muscle, bone, or joint pain;
  • tiredness;
  • nausea, diarrhea;
  • rash; or
  • abnormal blood tests.

Rare’

  • Bladder pain
  • bloating
  • bloody or cloudy urine
  • burning urination
  • coughing up blood
  • frequent urge to urinate
  • increased menstrual flow or vaginal bleeding
  • indigestion
  • nosebleeds
  • pains in the chest, groin, or legs, especially calves of the legs
  • pains in the stomach, side, or abdomen, possibly radiating to the back
  • paralysis
  • prolonged bleeding from cuts
  • severe headaches of sudden onset
  • sudden loss of coordination
  • sudden onset of slurred speech
  • sudden vision changes
  • vomiting
  • yellow eyes or skin

Drug Interaction

 

Pregnancy and Lactation

Pregnancy

Based on findings from animal studies and the mechanism of action, SCEMBLIX can cause embryo-fetal harm when administered to a pregnant woman. There are no available data on SCEMBLIX use in pregnant women to evaluate a drug-associated risk.

Animal reproduction studies in pregnant rats and rabbits demonstrated that oral administration of asciminib during
organogenesis-induced structural abnormalities, embryo-fetal mortality, and alterations to growth. Advise pregnant women and females of reproductive potential of the potential risk to a fetus. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively.

Lactation

There are no data on the presence of asciminib or its metabolites in human milk, the effects on the breastfed child, or milk
production. Because of the potential for serious adverse reactions in the breastfed child, advise women not to breastfeed during
treatment with SCEMBLIX and for 1 week after the last dose.

What special precautions should I follow?

Before taking asciminib,

  • tell your doctor and pharmacist if you are allergic to asciminib, any other medications, or any of the ingredients in asciminib. Ask your pharmacist for a list of the ingredients.
  • tell your doctor and pharmacist what other prescription and nonprescription medications, vitamins, and nutritional supplements you are taking or plan to take. Be sure to mention any of the following: anticoagulants (”blood thinners”) such as warfarin (Coumadin, Jantoven), apixaban (Eliquis), or dabigatran (Pradaxa); certain antifungals such as fluconazole (Diflucan), itraconazole (Onmel, Sporanox), ketoconazole (Nizoral), and voriconazole (Vfend); clarithromycin (Biaxin, in PrevPac); clopidogrel (Plavix); dexamethasone; certain medications used to treat diabetes such as glimepiride (Amaryl), glipizide (Glucotrol), glyburide (Diabeta), and rosiglitazone (Avandia); certain medications used to treat human immunodeficiency virus (HIV) such as atazanavir (Reyataz), dolutegravir (Tivicay, in Dovato, Juluca, Triumeq), indinavir (Crixivan), nelfinavir (Viracept), rilpivirine (Edurant, in Cabenuva Kit, Complera, Juluca, Odefsey); and ritonavir (Norvir); certain medications used to treat high blood pressure such as amlodipine (Norvasc, in Caduet, Exforge, Lotrel), diltiazem (Cardizem), irbesartan (Avapro, in Avalide), losartan (Cozaar), and verapamil (Calan, Verelan); certain medications used to treat high cholesterol such as atorvastatin (Lipitor), fluvastatin (Lescol XL), lovastatin (Altoprev), and simvastatin (Zocor, Flolipid, in Vytorin); and certain medications used to treat seizures such as carbamazepine (Tegretol), diazepam (Valium), phenytoin (Dilantin), and valproic acid (Depakene). Also tell your doctor if you are taking itraconazole oral solution as it may contain an inactive ingredient that my interact with asciminib. Many other medications may also interact with asciminib, so be sure to tell your doctor about all the medications you are taking, even those that do not appear on this list. Your doctor may recommend against use of asciminib or need to change the doses of your medications or monitor you carefully for side effects.
  • tell your doctor if you are pregnant or plan to become pregnant. You should not become pregnant while you are taking asciminib and for 1 week after your final dose. Talk to your doctor about birth control methods that will work for you. If you become pregnant while taking asciminib, call your doctor. Asciminib may harm the fetus.
  • do not breastfeed while taking asciminib and for 1 week after your final dose.
  • you should know that this medication may decrease fertility in women. Talk to your doctor about the risks of taking asciminib.

References

  1. https://pubchem.ncbi.nlm.nih.gov/compound/Asciminib
  2. https://pubchem.ncbi.nlm.nih.gov/compound/Asciminib-hydrochloride
  3. https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-asciminib-philadelphia-chromosome-positive-chronic-myeloid-leukemia
  4. https://medlineplus.gov/druginfo/meds/a621055.html
  5. https://www.drugs.com/mtm/asciminib.html
  6. https://www.cancer.gov/about-cancer/treatment/drugs/asciminib-hydrochloride
  7. https://www.webmd.com/drugs/2/drug-182620/asciminib-oral/details/list-contraindications
  8. ChEMBL
    http://www.ebi.ac.uk/Information/termsofuse.html
    https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL4208229/
    ChEMBL Protein Target Tree
    https://www.ebi.ac.uk/chembl/g/#browse/targets
  9. Drug Gene Interaction database (DGIdb)
    http://www.dgidb.org/downloads
    https://www.dgidb.org/drugs/ASCIMINIB
  10. DrugBank
    https://www.drugbank.ca/legal/terms_of_use
    Asciminib
    https://www.drugbank.ca/drugs/DB12597
  11. IUPHAR/BPS Guide to PHARMACOLOGY
    https://www.guidetopharmacology.org/about.jsp#license
    https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8962
    Guide to Pharmacology Target Classification
    https://www.guidetopharmacology.org/targets.jsp
  12. ChemIDplus
    LICENSE
    https://www.nlm.nih.gov/copyright.html
    Asciminib [USAN]
    https://chem.nlm.nih.gov/chemidplus/sid/1492952767
    ChemIDplus Chemical Information Classification
    https://chem.nlm.nih.gov/chemidplus/
  13. European Chemicals Agency (ECHA)
    https://echa.europa.eu/web/guest/legal-notice
    (R)-N-(4-(chlorodifluoromethoxy)phenyl)-6-(3-hydroxypyrrolidin-1-yl)-5-(1H-pyrazol-5-yl)nicotinamide
    https://echa.europa.eu/information-on-chemicals
  14. FDA Global Substance Registration System (GSRS)
    https://www.fda.gov/about-fda/about-website/website-policies#linking
    ASCIMINIB
    https://gsrs.ncats.nih.gov/ginas/app/beta/substances/L1F3R18W77
  15. ClinicalTrials.gov
    https://clinicaltrials.gov/ct2/about-site/terms-conditions#Use
    https://clinicaltrials.gov/
  16. NCI Thesaurus (NCIt)
    https://www.cancer.gov/policies/copyright-reuse
    https://ncithesaurus.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&ns=ncit&code=C114494
    NCI Thesaurus Tree
    https://ncit.nci.nih.gov
  17. European Medicines Agency (EMA)
    https://www.ema.europa.eu/en/about-us/legal-notice
    Scemblix (EMEA/H/C/005605)
    https://www.ema.europa.eu/en/medicines/human/EPAR/scemblix
  18. EU Clinical Trials Register
    https://www.clinicaltrialsregister.eu/
  19. FDA Orange Book
    https://www.fda.gov/about-fda/about-website/website-policies#linking
    https://www.fda.gov/drugs/drug-approvals-and-databases/approved-drug-products-therapeutic-equivalence-evaluations-orange-book
  20. WHO Anatomical Therapeutic Chemical (ATC) Classification
    https://www.whocc.no/copyright_disclaimer/
    https://www.whocc.no/atc/
    ATC Code
    https://www.whocc.no/atc_ddd_index/
  21. National Drug Code (NDC) Directory
    https://www.fda.gov/about-fda/about-website/website-policies#linking
    ASCIMINIB
    https://www.fda.gov/drugs/drug-approvals-and-databases/national-drug-code-directory
  22. NCI Cancer Drugs
    LICENSE
    https://www.cancer.gov/policies/copyright-reuse
    Asciminib Hydrochloride
    https://www.cancer.gov/about-cancer/treatment/drugs/asciminib-hydrochloride
  23. NIPH Clinical Trials Search of Japan
    https://rctportal.niph.go.jp/en/
  24. NLM RxNorm Terminology
    https://www.nlm.nih.gov/research/umls/rxnorm/docs/termsofservice.html
    https://rxnav.nlm.nih.gov/id/rxnorm/2584304
  25. Protein Data Bank in Europe (PDBe)
    http://www.ebi.ac.uk/pdbe-srv/pdbechem/chemicalCompound/show/AY7
  26. PubChem
    https://pubchem.ncbi.nlm.nih.gov
    PFAS and Fluorinated Compounds in PubChem
    https://gitlab.lcsb.uni.lu/eci/pubchem-docs/-/raw/main/pfas-tree/PFAS_Tree.pdf?inline=false
  27. RCSB Protein Data Bank (RCSB PDB)
    https://www.rcsb.org/pages/policies
    https://www.rcsb.org/
  28. Springer Nature
    https://pubchem.ncbi.nlm.nih.gov/substance/?source=15745&sourceid=31052316-173635866
  29. Thieme Chemistry
    https://creativecommons.org/licenses/by-nc-nd/4.0/
    https://pubchem.ncbi.nlm.nih.gov/substance/?source=22163&sourceid=31052316-173633790
  30. Wikidata
    LICENSE
    CCZero
    https://creativecommons.org/publicdomain/zero/1.0/
    Asciminib
    https://www.wikidata.org/wiki/Q27074535
  31. Medical Subject Headings (MeSH)
    https://www.nlm.nih.gov/copyright.html
    asciminib
    https://www.ncbi.nlm.nih.gov/mesh/2021404
    MeSH Tree
    http://www.nlm.nih.gov/mesh/meshhome.html
  32. KEGG
    LICENSE
    Academic users may freely use the KEGG website. Non-academic use of KEGG generally requires a commercial license
    https://www.kegg.jp/kegg/legal.html
    Anatomical Therapeutic Chemical (ATC) classification
    http://www.genome.jp/kegg-bin/get_htext?br08303.keg
    Target-based classification of drugs
    http://www.genome.jp/kegg-bin/get_htext?br08310.keg
    Drug Groups
    http://www.genome.jp/kegg-bin/get_htext?br08330.keg
  33. NORMAN Suspect List Exchange
    LICENSE
    Data: CC-BY 4.0; Code (hosted by ECI, LCSB): Artistic-2.0
    https://creativecommons.org/licenses/by/4.0/
    NORMAN Suspect List Exchange Classification
    https://www.norman-network.com/nds/SLE/
  34. PATENTSCOPE (WIPO)
    SID 393864963
    https://pubchem.ncbi.nlm.nih.gov/substance/393864963

RX Clinical Pathway Engine

Continue through a complete learning pathway

Move from understanding the topic to symptoms, tests, treatment, medicines, monitoring, and prevention.

Search the complete library
  1. Understand the condition Begin with the essential facts and a clear explanation of the topic.
  2. Recognize symptoms Learn common symptoms, signs, and patterns of presentation.
  3. Know when to seek help Review urgent warning signs and when professional assessment may be needed.
  4. Understand causes and risks Explore causes, risk factors, mechanisms, and contributing conditions.
  5. Explore tests and diagnosis Learn how clinicians assess the condition and which investigations may be discussed.
  6. Learn treatment approaches Review general treatment categories and management principles.
  7. Understand medicines safely Continue to medicine education, uses, precautions, and monitoring.
  8. Plan monitoring and follow-up Understand monitoring, complications, rehabilitation, and follow-up learning.
  9. Review prevention and self-care Explore prevention, healthy routines, and questions to discuss with a clinician.

Conditions & Diseases

Background, symptoms, causes, diagnosis, and care.

Explore this library

Tests & Investigations

Laboratory, imaging, screening, and diagnostic education.

Explore this library

Medicines

Uses, safety, monitoring, and related medicine knowledge.

Explore this library

Cancer Knowledge

Cancer types, screening, oncology, and treatment education.

Explore this library
Doctor visit helper

Prepare before seeing a doctor

A simple rural-patient checklist to help you explain symptoms clearly, ask better questions, and avoid unsafe self-treatment.

Safety note: This is not a prescription or diagnosis. For severe symptoms, pregnancy danger signs, children with serious illness, chest pain, breathing difficulty, stroke-like weakness, or major injury, seek urgent care.

Which doctor may help?

Start with a registered doctor or the nearest qualified health center.

What to tell the doctor

  • Write when the problem started and how it changed.
  • Bring old prescriptions, investigation reports, and current medicines.
  • Write allergies, pregnancy status, diabetes, kidney/liver disease, and major past illnesses.
  • Bring one family member if the patient is weak, elderly, confused, or a child.

Questions to ask

  • What is the most likely cause of my symptoms?
  • Which danger signs mean I should go to hospital quickly?
  • Which tests are necessary now, and which can wait?
  • How should I take medicines safely and what side effects should I watch for?
  • When should I come for follow-up?

Tests to discuss

  • Vital signs: temperature, pulse, blood pressure, oxygen saturation
  • Basic physical examination by a clinician
  • CBC, urine test, blood sugar, or imaging only when clinically needed

Avoid these mistakes

  • Do not use antibiotics, steroid tablets/injections, or strong painkillers without proper medical advice.
  • Do not hide pregnancy, kidney disease, ulcer, allergy, or blood thinner use.
  • Do not delay emergency care when danger signs are present.

Medicine safety and first-aid guide

This section is for patient education only. It does not replace a doctor, pharmacist, or emergency care.

Safe first steps

  • Avoid heavy lifting, sudden bending, and prolonged bed rest.
  • Use comfortable posture and gentle movement as tolerated.
  • Discuss physiotherapy, X-ray, or MRI only when clinically needed.

OTC medicine safety

  • For mild back pain, pain-relief medicine may be discussed with a doctor or pharmacist.
  • Avoid repeated painkiller use if you have kidney disease, stomach ulcer, uncontrolled blood pressure, or are taking blood thinners.

Avoid these mistakes

  • Do not start antibiotics without a proper medical decision.
  • Do not use steroid tablets or injections casually for quick relief.
  • Do not delay emergency care because of home remedies.

Get urgent help if

  • Back pain with leg weakness, numbness around private area, loss of urine/stool control, fever, cancer history, or major injury needs urgent care.
Medicine names, dose, and timing must be decided by a qualified clinician or pharmacist after checking age, pregnancy, allergy, other diseases, and current medicines.

For rural patients and family caregivers

Patient health record and symptom diary

Write your symptoms, medicines already taken, test results, and questions before visiting a doctor. This note stays on your device unless you print or copy it.

Doctor to discuss: Medicine doctor / pediatrician for children / qualified clinician
Tests to discuss with doctor
  • Temperature chart and hydration assessment
  • CBC with platelet count if fever persists or dengue/other infection is possible
  • Urine test, malaria/dengue tests, chest evaluation, or blood culture only when clinically indicated
Questions to ask
  • What is the most likely cause of my symptoms?
  • Which warning signs mean I should go to emergency care?
  • Which tests are really needed now?
  • Which medicines are safe for my age, pregnancy status, allergy, kidney/liver/stomach condition, and current medicines?
  • Do I need antibiotics, or is this more likely viral?

Emergency warning signs such as chest pain, severe breathing difficulty, sudden weakness, confusion, severe dehydration, major injury, or loss of bladder/bowel control need urgent medical care. Do not wait for online information.

Safe pathway to proper treatment

Care roadmap for: Asciminib – Uses, Dosage, Side Effects, Interaction

Use this simple roadmap to understand the next safe steps. It is educational and does not replace examination by a doctor.

Go to emergency care if you notice:
  • Severe or rapidly worsening symptoms
  • Breathing difficulty, chest pain, fainting, confusion, severe weakness, major injury, or severe dehydration
Doctor / service to discuss: Qualified healthcare provider; specialist depends on symptoms and examination.
  1. Step 1

    Check danger signs first

    If danger signs are present, seek emergency care and do not wait for online information.

  2. Step 2

    Record the symptom story

    Write when symptoms started, severity, medicines already taken, allergies, pregnancy status, and test results.

  3. Step 3

    Visit a qualified clinician

    A doctor, nurse, or qualified healthcare provider can examine you and decide which tests or treatment are needed.

  4. Step 4

    Do only useful tests

    Do tests after clinical assessment. Avoid unnecessary tests, random antibiotics, or repeated medicines without diagnosis.

  5. Step 5

    Follow up and return early if worse

    If symptoms worsen, new warning signs appear, or treatment is not helping, return for review quickly.

Rural patient practical tips
  • Take a written symptom diary and all previous prescriptions/test reports.
  • Do not hide medicines already taken, even herbal or over-the-counter medicines.
  • Ask which warning signs mean urgent referral to hospital.

This roadmap is for education. A real diagnosis and treatment plan requires history, examination, and clinical judgment.

RX Patient Help

Ask a health question safely

Write your symptom story. A health professional or site editor can review it before any answer is prepared. This box is not for emergency care.

Emergency first: Severe chest pain, breathing trouble, unconsciousness, stroke signs, severe injury, heavy bleeding, or rapidly worsening symptoms need urgent local medical care now.

Frequently Asked Questions

Is this article a replacement for a doctor?

No. It is educational content only. Patients should consult a qualified clinician for diagnosis and treatment.

When should I seek urgent care?

Seek urgent care for severe symptoms, rapidly worsening condition, breathing difficulty, severe pain, neurological changes, or any emergency warning sign.

Continue exploring

Explore this topic across the RX Medical Library

Open a focused A–Z pathway or continue with closely related indexed articles. These links are educational and do not replace personal medical care.

Search this topic
Diseases A–Z Drugs A–Z Lab Tests A–Z Cancer A–Z
Diseases A–Z

Foodborne Illness (also foodborne disease and colloquially referred to as food poisoning)[rx] is any illness resulting from the spoilage of contaminated food, pathogenic bacteria, viruses, or parasites that…

More from this topic
  1. Vasodilator Drugs

    Vasodilator drugs relax and widen blood vessels, increasing blood flow. A few examples include ACE inhibitors, ARBs, calcium channel blockers, and nitrates.   DefinitionVasodilators are medicines that dilate...

    June 9, 2025 • Drugs (A - Z)
  2. Methamphetamine Hydrochloride – Uses, Dosage, Side Effects, Interaction

    Methamphetamine Hydrochloride is the hydrochloride salt form of methamphetamine, an amphetamine and sympathomimetic amine with CNS stimulating properties. Methamphetamine hydrochloride acts by facilitating the release of catecholamines, particularly noradrenaline and dopamine, from...

    June 5, 2025 • Drugs (A - Z)
  3. Methamphetamine – Uses, Dosage, Side Effects, Interactions

    Methamphetamine is a member of the class of amphetamines in which the amino group of (S)-amphetamine carries a methyl substituent. It has a role as a neurotoxin, a psychotropic drug,...

    June 5, 2025 • Drugs (A - Z)
  4. Vitamin D3 – Uses, Dosage, Side Effects, Interactions

    DefinitionCholecalciferol is a steroid? hormone produced in the skin when exposed to ultraviolet light or obtained from dietary sources. The active form of cholecalciferol, 1,25-dihydroxycholecalciferol (calcitriol) plays an important role...

    March 10, 2025 • Drugs (A - Z)
  5. Imidazole – Uses, Dosage, Side Effects, Interactions

    DefinitionImidazole is an imidazole tautomer which has the migrating hydrogen at position 1. It is a conjugate base of an imidazolium cation. It is a conjugate acid of an imidazolide. It is...

    October 20, 2023 • Drugs (A - Z)
  6. Carbimazole

    Carbimazole is a member of the class of imidazoles that is methimazole in which the nitrogen-bearing hydrogen is converted into its methoxycarbonyl derivative. A prodrug for methimazole, carbimazole is...

    October 20, 2023 • Drugs (A - Z)
  7. Methylthiouracil – Uses, Dosage, Side Effects, Interactions

    DefinitionA thiourea antithyroid agent that inhibits the synthesis of thyroid? hormone. It is used in the treatment of hyperthyroidism?. Methylthiouracil is an organosulfur compound that is used in...

    October 20, 2023 • Drugs (A - Z)
  8. Propylthiouracil – Uses, Dosage, Side Effects, Interactions

    DefinitionPropylthiouracil is a Thyroid? Hormone Synthesis Inhibitor. The mechanism of action of propylthiouracil is as a Thyroid Hormone Synthesis Inhibitor. 6-propyl-2-thiouracil is a pyrimidine-thione consisting of uracil in which the...

    October 20, 2023 • Drugs (A - Z)
  9. Methimazole

    DefinitionMethimazole ( Metirox 5 and 10 mg) is a member of the class of imidazoles that it imidazole-2-thione in which a methyl group replaces the hydrogen that is attached to...

    October 20, 2023 • Drugs (A - Z)
  10. Mirogabalin – Uses, Dosage, Side Effects, Interactions

    DefinitionMirogabalin has been used in trials studying the treatment of Post-herpetic Neuralgia, Pain? Associated With Fibromyalgia, and Diabetic peripheral neuropathic pain. Mirogabalin is a medication designed...

    August 12, 2023 • Drugs (A - Z)